{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T21:24:17Z","timestamp":1792185857382,"version":"4.4.0"},"reference-count":36,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2016,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            There is an urgent need for the development of an antigonococcal vaccine due to the increasing drug resistance found in this pathogen. The U.S. Centers for Disease Control (CDC) have identified multidrug-resistant gonococci (GC) as among 3 \u201curgent\u201d hazard-level threats to the U.S. population. In light of this, on 29 to 30 June 2015, the National Institute for Allergy and Infectious Diseases (NIAID) sponsored a workshop entitled \u201cGonorrhea Vaccines: the Way Forward.\u201d The goal of the workshop was to gather leaders in the field to discuss several key questions on the current status of gonorrhea vaccine research and the path forward to a licensed gonorrhea vaccine. Representatives from academia, industry, U.S. Government agencies, and a state health department were in attendance. This review summarizes each of the 4 scientific sessions and a series of 4 breakout sessions that occurred during the one and a half days of the workshop. Topics raised as high priority for future development included (i) reinvigoration of basic research to understand gonococcal infection and immunity to allow intervention in processes essential for infection; (ii) clinical infection studies to establish parallels and distinctions between\n            <jats:italic>in vitro<\/jats:italic>\n            and animal infection models versus natural human genital and pharyngeal infection and to inform\n            <jats:italic>in silico<\/jats:italic>\n            modeling of vaccine impact; and (iii) development of an integrated pipeline for preclinical and early clinical evaluation and direct comparisons of potential vaccine antigens and adjuvants and routes of delivery.\n          <\/jats:p>","DOI":"10.1128\/cvi.00230-16","type":"journal-article","created":{"date-parts":[[2016,6,23]],"date-time":"2016-06-23T14:22:53Z","timestamp":1466691773000},"page":"656-663","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":37,"title":["Summary and Recommendations from the National Institute of Allergy and Infectious Diseases (NIAID) Workshop \u201cGonorrhea Vaccines: the Way Forward\u201d"],"prefix":"10.1128","volume":"23","author":[{"given":"Lee M.","family":"Wetzler","sequence":"first","affiliation":[{"name":"Section of Infectious Diseases, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian M.","family":"Feavers","sequence":"additional","affiliation":[{"name":"National Institute for Biological Standards and Control, Hertfordshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Gray-Owen","sequence":"additional","affiliation":[{"name":"Department of Molecular Genetics, University of Toronto, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann E.","family":"Jerse","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, F. Edward H\u00e9bert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Rice","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn D.","family":"Deal","sequence":"additional","affiliation":[{"name":"Division of Microbiology and Infectious Diseases, NIAID, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0143304"},{"key":"e_1_3_2_3_2","unstructured":"Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States. CDC Atlanta GA. http:\/\/www.cdc.gov\/drugresistance\/pdf\/ar-threats-2013-508.pdf."},{"key":"e_1_3_2_4_2","unstructured":"The White House. 2015. National action plan for combating antibiotic-resistant bacteria. The White House Washington DC. https:\/\/www.whitehouse.gov\/sites\/default\/files\/docs\/national_action_plan_for_combating_antibotic-resistant_bacteria.pdf."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.01.050"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.vaccine.2014.01.053","article-title":"Vaccines against sexually transmitted infections: the way forward","volume":"32","author":"Broutet N","year":"2014","unstructured":"Broutet N, Fruth U, Deal C, Gottlieb SL, Rees H; participants of the 2013 STI Vaccine Technical Consultation. 2014. Vaccines against sexually transmitted infections: the way forward. Vaccine. 32:1630\u20131637.","journal-title":"Vaccine"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2011.00052"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(91)90147-X"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa0707052"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5775"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13494-0"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.03.034"},{"key":"e_1_3_2_13_2","first-page":"29","article-title":"Gonococcal vaccine studies in Inuvik","volume":"65","author":"Greenberg L","year":"1974","unstructured":"Greenberg L, Diena BB, Ashtron FA, Wallace R, Kenney CP, Znamirowski R, Ferrari H, Atkinson J. 1974. Gonococcal vaccine studies in Inuvik. Can J Public Health 65:29\u201333.","journal-title":"Can J Public Health"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.2.Suppl.S74"},{"key":"e_1_3_2_15_2","first-page":"3","volume-title":"Pathogenic neisseria","author":"Rice PA","year":"1996","unstructured":"Rice PA, Gulati S, McQuillen DP, Ram S. 1996. Is there protective immunity to gonococcal disease, p 3\u20138. In Zollinger WD, Frasch CE, Deal CD (ed), Pathogenic neisseria. 10th International Pathogenic Neisseria Conference. National Institutes of Health, Bethesda, MD."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI114040"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117159"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116190"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/174.6.1223"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003559"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2011.00123"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/169.3.532"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/172.1.180"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.17.4.965-981.2004"},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1128\/IAI.67.6.3009-3013.1999","article-title":"A Neisseria gonorrhoeae immunoglobulin A1 protease mutant is infectious in the human challenge model of urethral infection","volume":"67","author":"Johannsen DB","year":"1999","unstructured":"Johannsen DB, Johnston DM, Koymen HO, Cohen MS, Cannon JG. 1999. A Neisseria gonorrhoeae immunoglobulin A1 protease mutant is infectious in the human challenge model of urethral infection. Infect Immun 67:3009\u20133013.","journal-title":"Infect Immun"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2958.1998.00710.x"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/172.1.186"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007435-200110000-00001"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2011.00107"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1086\/315801"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2011.00124"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit354"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2015.122"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00260-13"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.02572-14"},{"key":"e_1_3_2_36_2","unstructured":"U.S. Food and Drug Administration. 2014. Guidance for industry: expedited programs for serious conditions\u2014drugs and biologics. U.S. Food and Drug Administration Baltimore MD. http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm358301.pdf."},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.07.015"}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00230-16","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00230-16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T01:10:12Z","timestamp":1622077812000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00230-16"}},"subtitle":[],"editor":[{"given":"C. J.","family":"Papasian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["10.1128\/CVI.00230-16"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00230-16","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"2016-08-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}